Core Viewpoint - West Point Pharmaceutical (301130) has launched a treatment for mild to moderate Alzheimer's disease, aiming to capitalize on the aging population and enhance the quality of life for the elderly [1] Group 1: Product Development - The oral solution of Rivastigmine tartrate for treating Alzheimer's disease is set to be launched in 2025 [1] Group 2: Strategic Goals - The company adheres to the strategic goal of improving the quality of life for the elderly, emphasizing dignity in their later years [1] - West Point Pharmaceutical has undertaken a series of strategic initiatives to build a product matrix focused on aging-related health [1] Group 3: Market Positioning - The company aims to become a strong competitor in the domestic silver-haired health medication market, leveraging long-term opportunities presented by population aging [1]